Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic inhibition of glutamate-cysteine ligase increases dendritic cell-mediated antitumor immunity in melanoma.

Journal for immunotherapy of cancer·2026
Same author

Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling.

Nature medicine·2026
Same author

Current challenges in standardising classification and management of locally advanced cutaneous squamous cell carcinoma.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Psoriasis Area and Severity Index Training via Virtual Reality Application: New Way of Effective Teaching.

Dermatology (Basel, Switzerland)·2026
Same author

Targeting the G-protein-coupled estrogen receptor: a novel therapeutic strategy in cutaneous T-cell lymphoma.

Blood neoplasia·2026
Same author

Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma.

BMC cancer·2026

Related Experiment Video

Updated: Jun 28, 2026

High-throughput Synthesis of Carbohydrates and Functionalization of Polyanhydride Nanoparticles
14:37

High-throughput Synthesis of Carbohydrates and Functionalization of Polyanhydride Nanoparticles

Published on: July 6, 2012

11.0K

Targeting Langerhans cells using a modular mannosylated nucleic acid-based vaccine platform.

Simon Christian Vinther1, Antonia Resag2, Karina Thao Thu Le1

  • 1Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Aarhus C, Denmark.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|February 19, 2026
PubMed
Summary

Researchers developed a novel nucleic acid scaffold to precisely target Langerhans cells in the skin. This platform enhances drug delivery and T cell activation for advanced skin immunotherapies.

Keywords:
Antigen presentationLangerhans cellNucleic acidsSkin immunizationTargeted deliveryVaccine

More Related Videos

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
11:07

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

12.2K
Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
10:35

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

3.0K

Related Experiment Videos

Last Updated: Jun 28, 2026

High-throughput Synthesis of Carbohydrates and Functionalization of Polyanhydride Nanoparticles
14:37

High-throughput Synthesis of Carbohydrates and Functionalization of Polyanhydride Nanoparticles

Published on: July 6, 2012

11.0K
Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
11:07

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

12.2K
Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
10:35

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

3.0K

Area of Science:

  • Immunology
  • Biotechnology
  • Materials Science

Background:

  • The skin harbors immune cells, including Langerhans cells (LCs) in the epidermis, which are key for antigen presentation and immunotherapy.
  • Targeting LCs via their surface receptor, Langerin, with carbohydrate-conjugated therapeutics offers a promising route for vaccination and drug delivery.
  • Optimizing carbohydrate-lectin interactions requires precise control over ligand spacing and valency on delivery scaffolds.

Purpose of the Study:

  • To design and evaluate a novel nucleic acid-based scaffold for targeted delivery to skin Langerhans cells.
  • To investigate the role of scaffold valency and carbohydrate arrangement in enhancing binding to Langerin.
  • To assess the efficacy of the scaffold for enhancing antigen presentation and T cell activation.

Main Methods:

  • Utilized self-assembled nucleic acid Holliday Junctions as a scaffold, modified for stability and precise carbohydrate arrangement.
  • Performed in vitro screening using Langerin-expressing cells and human epidermal cell suspensions to assess binding specificity and valency-driven interactions.
  • Evaluated topical delivery on skin explants and antigen-presentation assays with in vitro differentiated LCs.

Main Results:

  • Mannosylated Holliday Junction scaffolds demonstrated the strongest binding to Langerin in vitro and in human epidermal cells.
  • Specificity and valency-dependent interactions were confirmed, showing effective targeting of epidermal Langerhans cells upon topical administration.
  • Scaffolds loaded with mannose and peptide conjugates significantly enhanced T cell activation in antigen-presentation assays.

Conclusions:

  • Developed a nuclease-protected, self-assembled nucleic acid platform for precise Langerhans cell targeting.
  • Demonstrated valency-driven, specific targeting of LCs via Langerin using mannosylated scaffolds.
  • The platform shows significant potential for enhancing skin-directed immunotherapies by improving antigen presentation and T cell activation.